Serum hepatocyte growth factor levels predict long-term clinical outcome after percutaneous coronary revascularization.
OBJECTIVE
To evaluate, in patients referred for elective percutaneous coronary revascularization (PCR) without heparin pre-treatment, the relationship between baseline serum levels of the angiogenic growth factors, vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), and clinical outcome.


RESULTS
In 488 consecutive patients undergoing elective coronary angioplasty, hsC-reactive protein, HGF, and VEGF levels were measured before heparin administration. The primary endpoint, a composite of death and myocardial infarction, occurred in 44 patients at a median follow-up of 14.9 months. At baseline, VEGF levels were related to C-reactive protein levels and inversely related to age; HGF levels were related to C-reactive protein levels, diabetes, and recent clinical instability. In the univariate analysis, HGF had a significant positive relationship (P=0.003) with the primary endpoint. A similar trend was observed for VEGF (P=0.11). The only three variables significantly associated with the primary endpoint in the multivariable Cox model were HGF (P=0.004), C-reactive protein (P=0.007), and diabetes (P=0.04).


CONCLUSIONS
Our results demonstrate that in patients, without heparin pre-treatment, referred for PCR, a high serum level of HGF is an independent predictor of clinical events during follow-up and is correlated with other surrogate measures of the activity of atherosclerosis.
Susen
Sophie
S
Department of Hematology, University Hospital, Lille, France.
Sautière
Karine
K
Mouquet
Frédéric
F
Cuilleret
François
F
Chmaït
Akram
A
McFadden
Eugène P
EP
Hennache
Bernadette
B
Richard
Florence
F
de Groote
Pascal
P
Lablanche
Jean-Marc
JM
Dallongeville
Jean
J
Bauters
Christophe
C
Jude
Brigitte
B
Van Belle
Eric
E
D000368:Aged; D000787:Angina Pectoris / Q000097:blood / Q000209:etiology / Q000628:therapy; D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D015415:Biomarkers / Q000097:blood; D003324:Coronary Artery Disease / Q000097:blood / Q000209:etiology; D003925:Diabetic Angiopathies / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D017228:Hepatocyte Growth Factor / Q000097:blood*; D006801:Humans; D006973:Hypertension / Q000097:blood; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009203:Myocardial Infarction / Q000097:blood / Q000628:therapy*; D009204:Myocardial Revascularization / Q000379:methods*; D011379:Prognosis; D018570:Risk Assessment; D015607:Stents; D042461:Vascular Endothelial Growth Factor A / Q000097:blood*
D015415:Biomarkers; D042461:Vascular Endothelial Growth Factor A; D017228:Hepatocyte Growth Factor